Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.77 -3.37%

-$0.34 today

Market cap
$186.36M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.97M

Average 0.48M

ARTV Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Artiva Biotherapeutics, Inc.NASDAQ: ARTV

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity falls 48.0% from a year ago

Total equity stood at $87.85M at the end of Q1 FY2026, down 48.0% from a year earlier and down 20.1% from the prior quarter.

Context

  • Total equity amounted to 82.9% of total assets at the end of Q1 FY2026, down 5.3 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -48.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$87.85M-20.1% QoQ
Last fiscal yearDec 2025
$109.97M-41.1% YoY
Year agoMar 2025
$168.78M-48.0% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-48.0%——
1 year-41.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
109.97M USD
Year-over-year change
-41.1%

Total Equity vs competitors

How ARTV compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -48.0% is the 7th highest of 9, against a peer median of +1.8%.
  • Total equity amounts to 82.9% of total assets for ARTV, versus a peer median of 73.5%.
ARTV Competitors
Total Equity for ARTV and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$182.68M USD-38.2%-20.7%72.2%
ALXOALX Oncology Holdings Inc.Mar 2026$151.35M USD+71.4%-53.8%84.9%
STTKShattuck Labs, Inc.Mar 2026$95.84M USD+41.8%-22.4%93.8%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$87.85M USD-48.0%—82.9%
DTILPrecision BioSciences, Inc.Mar 2026$76.1M USD+54.2%+15.1%52.9%
CNTBConnect Biopharma Holdings LimitedDec 2025$41.98M USD-54.5%-35.6%74.9%
IFRXInflaRx N.V.Mar 2026€36.93M EUR-47.6%-22.2%75.5%
GUTSFractyl Health, Inc. Common StockMar 2026$21.38M USD+235.3%—21.5%
STROSutro Biopharma, Inc.Mar 2026-$66.89M USD-159.1%—27.6%
Peer median (excluding ARTV) —+1.8%-22.3%73.5%

Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents160.92M102.53M53.5M40.24M26.7M
Short-term Investments0023.47M145.19M81.31M
Net Receivables468K525K1.76M146K767K
Inventory00000
Other Current Assets01.62M1.09M3.06M3.89M
Total Current Assets162.29M104.68M79.82M188.63M112.67M
Property, Plant & Equipment (Net)4.08M27.62M24.64M20.43M17.36M
Goodwill00000
Intangible Assets00000
Long-term Investments0245K000
Tax Assets00000
Other Non-current Assets3.56M517K650K525K919K
Total Non-current Assets7.64M28.38M25.29M20.95M18.27M
Total Assets169.93M133.05M105.11M209.58M130.94M
Account Payables1.44M1.1M614K1.12M355K
Short-term Debt00003.06M
Tax Payables00000
Deferred Revenue7.3M10.89M000
Other Current Liabilities00002.1M
Total Current Liabilities19.31M25.63M12.23M12.25M13.09M
Long-term Debt00007.88M
Deferred Tax Liabilities216.41M216.41M000
Deferred Revenue (Non-current)21.68M15.64M000
Other Non-current Liabilities81K115K241.59M73K0
Total Non-current Liabilities239.48M248.13M254.9M10.69M7.88M
Total Liabilities258.78M273.75M267.13M22.94M20.97M
Common Stock0003K3K
Retained Earnings(93.8M)(152.59M)(181.31M)(246.68M)(330.55M)
Accumulated OCI00308K(129K)103K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(88.86M)(140.7M)(162.02M)186.64M109.97M
Total Debt1.74M19.45M16.91M14.35M10.94M
Net Debt(159.18M)(83.08M)(36.59M)(25.88M)(15.76M)

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Intrinsic Alpha fair value

Locked

Current Price

$3.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.